Mark R Hickman

List of Publications by Year
in descending order

40 papers	792 citations	471509 17 h-index	526287 27 g-index
41 all docs	41 docs citations	41 times ranked	1479 citing authors

#	Article	IF	Citations
1	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Neglected Tropical Diseases, 2022, 16, e0010220.	3.0	11
2	Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy, 2021, 65, e0073621.	3.2	6
3	Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Frontiers in Cellular and Infection Microbiology, 2020, 10, 203.	3.9	21
4	Prevalence of asymptomatic malaria infections in selected military camps in Tanzania. Tanzania Journal of Health Research, 2020, 21, 1-11.	0.2	3
5	Updating the modified Thompson test by using whole-body bioluminescence imaging to replace traditional efficacy testing in experimental models of murine malaria. Malaria Journal, 2019, 18, 38.	2.3	3
6	The use of Fionet technology for external quality control of malaria rapid diagnostic tests and monitoring health workersâ€™ performance in rural military health facilities in Tanzania. PLoS ONE, 2018, 13, e0208583.	2.5	6
7	Comparison of visual and automated Deki Reader interpretation of malaria rapid diagnostic tests in rural Tanzanian military health facilities. Malaria Journal, 2018, 17, 214.	2.3	8
8	Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a TieredIn VivoScreening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
9	Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites. Malaria Research and Treatment, 2017, 2017, 1-10.	2.0	10
10	Comparative Susceptibility of Different Mouse Strains to Liver-Stage Infection With Plasmodium berghei Sporozoites Assessed Using In Vivo Imaging. Military Medicine, 2017, 182, 360-368.	0.8	5
11	New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Scientific Reports, 2016, 6, 29179.	3.3	40
12	Pre-clinical evaluation of CYP 2D6 dependent drugâ€“drug interactions between primaquine and SSRI/SNRI antidepressants. Malaria Journal, 2016, 15, 280.	2.3	14
13	Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes. American Journal of Tropical Medicine and Hygiene, 2016, 94, 340-347.	1.4	27
14	Field evaluation of diagnostic performance of malaria rapid diagnostic tests in western Kenya. Malaria Journal, 2016, 15, 456.	2.3	47
15	Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei. Malaria Journal, 2016, 15, 588.	2.3	20
16	Assessment of the Worldwide Antimalarial Resistance Network Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field Samples with Various Initial Parasitemia Levels. Antimicrobial Agents and Chemotherapy, 2016, 60, 2417-2424.	3.2	21
17	The Impact of Pharmacokinetic Mismatched Antimalarial Drug Combinations on the Emergence and Spread of Drug Resistant Parasites. , 2015, , .		4
18	Modulating Acinetobacter baumannii biofilm development with molecules containing 3,4,5-trimethoxy-N,Nâ€²,Nâ€²-trimethylbenzohydrazide moiety. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2238-2242.	2.2	4

#	Article	IF	Citations
19	Direct Comparison of the Efficacy and Safety of Oral Treatments with Oleylphosphocholine (OlPC) and Miltefosine in a Mouse Model of L. major Cutaneous Leishmaniasis. PLoS Neglected Tropical Diseases, 2014, 8, e3144.	3.0	18
20	Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malaria Journal, 2014, 13, 2.	2.3	73
21	Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 57-65.	3.3	27
22	Auranofin Is an Apoptosis-Simulating Agent with in Vitro and in Vivo Anti-leishmanial Activity. ACS Chemical Biology, 2014, 9, 663-672.	3.4	56
23	Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. Malaria Journal, 2014, 13, 281.	2.3	13
24	Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malaria Journal, 2014, 13, 141.	2.3	46
25	Protective immune mechanisms against pre-erythrocytic forms of Plasmodium berghei depend on the target antigen. Trials in Vaccinology, 2014, 3, 6-10.	1.2	11
26	Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2035-2043.	2.2	21
27	3,5-Bis(benzylidene)-4-piperidones and related N-acyl analogs: A novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum. Bioorganic and Medicinal Chemistry, 2013, 21, 7250-7256.	3.0	5
28	From a cytotoxic agent to the discovery of a novel antimalarial agent. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 584-587.	2.2	3
29	Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3551-3555.	2.2	12
30	Drug Discovery Algorithm for Cutaneous Leishmaniasis. American Journal of Tropical Medicine and Hygiene, 2013, 88, 216-221.	1.4	31
31	Formulation and Particle Size Reduction Improve Bioavailability of Poorly Water-Soluble Compounds with Antimalarial Activity. Malaria Research and Treatment, 2013, 2013, 1-10.	2.0	19
32	Modification of Triclosan Scaffold in Search of Improved Inhibitors for Enoylâ€Acyl Carrier Protein (ACP) Reductase in Toxoplasma gondii. ChemMedChem, 2013, 8, 1138-1160.	3.2	20
33	An In vivo Drug Screening Model Using Glucose-6-Phosphate Dehydrogenase Deficient Mice to Predict the Hemolytic Toxicity of 8-Aminoquinolines. American Journal of Tropical Medicine and Hygiene, 2013, 88, 1138-1145.	1.4	9
34	Novel N -Benzoyl-2-Hydroxybenzamide Disrupts Unique Parasite Secretory Pathway. Antimicrobial Agents and Chemotherapy, 2012, 56, 2666-2682.	3.2	32
35	Salicylanilide Inhibitors of Toxoplasma gondii. Journal of Medicinal Chemistry, 2012, 55, 8375-8391.	6.4	45
36	Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 17-22.	1.6	17

#	Article	IF	Citations
37	Quantification of GPCR internalization by single-molecule microscopy in living cells. Integrative Biology (United Kingdom), 2011, 3, 675.	1.3	26
38	Therapeutic and Toxicological Inhibition of Vasculogenesis and Angiogenesis Mediated by Artesunate, a Compound with Both Antimalarial and Anticancer Efficacy. , 2011, , .		1
39	Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology, 2011, 279, 1-9.	4.2	35
40	Detection of influenza virus from throat and pharyngeal swabs with a nested duplex light cycler RT-PCR1. Diagnostic Microbiology and Infectious Disease, 2003, 46, 35-37.	1.8	6